118例多囊卵巢综合征患者的临床诊治分析

目的：探讨并比较二甲双胍、罗格列酮治疗多囊卵巢综合征的临床诊治疗效。方法：将我院2008年2月～2009年12月收治的118例高胰岛素血症的多囊卵巢综合征患者随机分为两组各59例，其中观察组给予二甲双胍治疗，对照组采用罗格列酮治疗，观察并比较两组空腹血胰岛素水平、睾酮、黄体生成素、促卵泡激素变化情况。结果：两组治疗后空腹血胰岛素水平、睾酮、黄体生成素均较治疗前有明显改善（p〈0.05）。二甲双胍治疗组治疗后空腹血胰岛素水平、睾酮、黄体生成素水平与罗格列酮治疗组治疗后水平比较有统计学差异（p〈0.05）.两组不良反应发生率比较有统计学差异（X^2=5．19，P〈0．05）。结论：临床治疗多囊卵巢综合征伴高胰岛素血症患者采用二甲双胍治疗更为理想。

118 patients with polycystic ovary syndrome Clinical analysis of patients

Objective： To evaluate and compare mefformin, rosiglitazone treatment polycystic ovarian syndrome patients. Methods： The hospital in February 2008 - December 2009 118 patients admitted to hyperinsulinemia in polycystic ovary syndrome were randomly divided into two groups of the 59 cases, including the observation group given metformin, the control group were Roger rosiglitazone treatment groups were observed and compared the level of fasting blood insulin, testosterone, luteinizing hormone, follicle stimulating hormone changes. Results： After treatment, fasting blood insulin, testosterone, luteinizing hormone significantly improved compared with before treatment （P 〈0.05）, decreased follicle-stimu- lating hormone levels were not significant （P〉 0.05）. After mefformin treatment, fasting blood insulin, testosterone, luteinizing hormone levels and rosiglitazone treatment group, compared the level of statistical significance （P 〈0.05）. The incidence of adverse reactions compared the two groups were significantly different （X^2 = 5.19, P 〈0.05）. Conclusion： The clinical treatment of PCOS patients with hyperinsulinemia by mefformin treatment is more ideal.